Samjin Pharm (005500) - Total Assets
Based on the latest financial reports, Samjin Pharm (005500) holds total assets worth ₩449.14 Billion KRW (≈ $304.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Samjin Pharm to assess how comfortably operating cash covers total debt obligations.
Samjin Pharm - Total Assets Trend (2013–2024)
This chart illustrates how Samjin Pharm's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Samjin Pharm for net asset value and shareholders' equity analysis.
Samjin Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Samjin Pharm's total assets of ₩449.14 Billion consist of 37.4% current assets and 62.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.8% |
| Accounts Receivable | ₩62.50 Billion | 14.7% |
| Inventory | ₩91.74 Billion | 21.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩21.52 Billion | 5.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Samjin Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Samjin Pharm.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samjin Pharm's current assets represent 37.4% of total assets in 2024, a decrease from 64.4% in 2013.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 1.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 21.6% of total assets.
Samjin Pharm Competitors by Total Assets
Key competitors of Samjin Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥7.80 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Samjin Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.05 | 4.15 |
| Quick Ratio | 0.52 | 0.45 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩37.31 Billion | ₩6.64 Billion | ₩123.14 Billion |
Samjin Pharm - Advanced Valuation Insights
This section examines the relationship between Samjin Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | ₩425.17 Billion |
| Market Capitalization | $152.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Samjin Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Samjin Pharm's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Samjin Pharm (2013–2024)
The table below shows the annual total assets of Samjin Pharm from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩425.17 Billion ≈ $288.13 Million |
+1.25% |
| 2023-12-31 | ₩419.90 Billion ≈ $284.56 Million |
+3.28% |
| 2022-12-31 | ₩406.56 Billion ≈ $275.52 Million |
+22.27% |
| 2021-12-31 | ₩332.50 Billion ≈ $225.33 Million |
+23.59% |
| 2020-12-31 | ₩269.03 Billion ≈ $182.32 Million |
+10.19% |
| 2019-12-31 | ₩244.15 Billion ≈ $165.46 Million |
-2.45% |
| 2018-12-31 | ₩250.27 Billion ≈ $169.61 Million |
+3.48% |
| 2017-12-31 | ₩241.85 Billion ≈ $163.90 Million |
+6.27% |
| 2016-12-31 | ₩227.57 Billion ≈ $154.22 Million |
+3.10% |
| 2015-12-31 | ₩220.74 Billion ≈ $149.59 Million |
+5.46% |
| 2014-12-31 | ₩209.31 Billion ≈ $141.84 Million |
+2.63% |
| 2013-12-31 | ₩203.95 Billion ≈ $138.21 Million |
-- |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more